HCPCS Code J0640: Leucovorin calcium injection billing guide

Key Takeaways

HCPCS Code J0640 describes injection of leucovorin calcium per 50 mg, billed as a Level II HCPCS J-code for physician-administered drugs

Medicare Part B covers J0640 under the buy-and-bill model at ASP+6%; pricing updates quarterly via CMS ASP files

NDC reporting is mandatory alongside J0640 on Medicare claims; omitting the NDC is a top denial trigger

Pabau’s claims management software helps oncology and infusion practices link J0640 billing directly to clinical documentation

HCPCS Code J0640: Definition and official descriptor

Most leucovorin calcium denials trace back to a single documentation gap: The claim arrives without a linked NDC number or a supporting ICD-10 diagnosis, and the payer has no basis to approve it. HCPCS Code J0640 covers injection of leucovorin calcium per 50 mg. It is a Level II HCPCS code maintained by the Centers for Medicare and Medicaid Services (CMS) and used across oncology practices, infusion centers, and physician offices to bill for this physician-administered drug.

This reference covers the billing rules, Medicare reimbursement methodology, fee schedule data, NDC crosswalk requirements, ICD-10 diagnoses, prior authorization considerations, and documentation standards that billers and coders need for accurate J0640 claim submission.

Clinical uses of leucovorin calcium

Leucovorin calcium has two distinct clinical roles, and the billing team needs to know which one applies because the supporting ICD-10 codes differ for each. Both are covered by HCPCS Code J0640, but the claim documentation changes depending on indication.

• Methotrexate rescue (MTX rescue): High-dose methotrexate therapy can cause life-threatening toxicity. Leucovorin is administered as a rescue agent to counteract methotrexate’s effects on healthy cells without reversing its antineoplastic action. According to FDA-approved labeling for leucovorin calcium, rescue dosing typically begins 24 hours after methotrexate administration and continues until methotrexate plasma levels fall below a safe threshold.
• 5-FU modulation in colorectal cancer: Leucovorin enhances the cytotoxic effect of fluorouracil (5-FU) in standard regimens such as FOLFOX and FOLFIRI. The combination is a backbone of metastatic colorectal cancer treatment, endorsed in clinical guidelines for first- and second-line therapy.
• Megaloblastic anemia: Leucovorin is used to treat megaloblastic anemia caused by folate deficiency when oral supplementation is not feasible, for example in patients with malabsorption syndromes.
• Nutritional deficiency/rescue after antifolate drugs: Some antifolate medications outside oncology (such as trimethoprim or pyrimethamine) can deplete folate stores, requiring leucovorin supplementation.

Practices running IV therapy EMR software often administer leucovorin as part of infusion protocols. Connecting the clinical indication to the J0640 claim at the point of documentation reduces the back-and-forth between clinicians and billing staff that delays reimbursement.

J0640 billing guidelines

Getting units right is where most J0640 errors start. The descriptor is “per 50 mg,” so each billable unit represents 50 mg of leucovorin calcium administered. A 200 mg dose = 4 units. A 500 mg dose = 10 units. Rounding up or down by even one unit creates either an underpayment or an overpayment audit flag.

Unit calculation rules

Bill only the dose actually administered, not the vial size purchased. If a 500 mg vial is opened and 200 mg administered, bill 4 units (200 mg / 50 mg), not 10. Wastage documentation may support billing the full vial under some payer policies, but Medicare requires documentation of the quantity administered.

Place of service codes

Place of service affects the Medicare payment rate. Physician offices (POS 11) typically receive the full Part B allowable. Hospital outpatient settings (POS 22) are subject to the outpatient prospective payment system (OPPS), which may result in a different reimbursement amount. Confirm the correct POS code with the administering facility before submitting.

Common billing errors to avoid

• Missing NDC number on the claim line (top denial reason for Part B drugs)
• Incorrect unit count (dose divided by 50, rounded to nearest whole unit based on administered amount)
• Mismatched ICD-10 diagnosis code that does not support leucovorin use
• Omitting the administration CPT code (96372 for subcutaneous/IM; 96374 for IV push) alongside J0640
• Using J0641 (levoleucovorin) when leucovorin calcium was administered

Pabau’s claims management software links administered drug records directly to claim generation, helping infusion and oncology practices reduce unit-count errors and missing-NDC denials before claims leave the practice.

Manage injectable drug billing without the spreadsheets

Pabau connects clinical administration records to claim submission so your billing team always has the dose, NDC, and diagnosis code in one place.

Book a demo

Medicare coverage and J0640 medicare reimbursement

Medicare Part B covers leucovorin calcium under the buy-and-bill model when administered in a physician office or outpatient setting. The practice purchases the drug, administers it, and bills Medicare for reimbursement. According to CMS Physician Fee Schedule guidance, Part B drugs reimbursed through the buy-and-bill pathway are paid at Average Sales Price (ASP) plus 6% as the add-on payment for handling and administration overhead.

CMS updates ASP pricing quarterly. The figures in effect for a given date of service depend on the quarter in which the drug was administered, not when the claim was submitted. Always verify current rates in the CMS HCPCS quarterly ASP drug pricing files before finalizing billing.

Good EHR integration for billing workflows is particularly valuable here: When the administration record captures the exact administered dose and date of service, the billing team can pull those details directly rather than reconstructing them from nursing notes or paper records.

J0640 fee schedule and drug pricing

Leucovorin calcium is a mature generic drug with multiple manufacturers, which keeps pricing relatively low compared to branded oncology agents. That said, the three pricing benchmarks billers encounter mean different things and should not be confused.

For current quarter ASP rates applicable to J0640, consult the CMS quarterly ASP drug pricing files directly. Because leucovorin has multiple generic manufacturers and NDC numbers, the reported ASP can vary slightly by source. The Medicare allowable is derived from a volume-weighted average across all reporting manufacturers.

NDC crosswalk for J0640

NDC reporting is not optional for Medicare Part B drug claims. CMS requires that the 11-digit National Drug Code number appear on the claim line alongside J0640, reported in the format 5-4-2 (labeler-product-package). Submitting a claim without the NDC, or with an NDC that does not cross-reference to the administered drug, triggers an automated denial.

How the NDC crosswalk works

Each manufacturer’s leucovorin calcium product carries a unique NDC. The crosswalk maps NDC numbers to J0640, confirming the correct J-code for billing. When purchasing leucovorin from a distributor, the invoice or package label carries the NDC. That exact NDC goes on the claim, not a generic or legacy number.

Common leucovorin calcium NDC families include products from manufacturers such as Pfizer, Sagent Pharmaceuticals, and West-Ward (Hikma), among others. Because pack sizes vary (50 mg/5 mL, 100 mg/10 mL, 200 mg/20 mL, 500 mg/50 mL), make sure the NDC on the claim matches the specific vial actually used. Using the wrong vial-size NDC even for the same manufacturer is a technical error that can be flagged in audit.

Pabau’s prescription management workflows allow practices to record administered drugs with their NDC at the point of care, so billing staff retrieve the correct NDC from the patient record rather than from memory or a separate spreadsheet.

NDC units and quantity reporting

On CMS 1500 claims, report the NDC quantity in the unit of measure matching the drug’s dispensed form. For leucovorin calcium solutions, this is typically milliliters (ML). The billing unit on the HCPCS code line (J0640 units = dose in mg / 50) and the NDC quantity line are separate fields that must be internally consistent but use different measures.

ICD-10 diagnosis codes used with J0640

Every J0640 claim needs a supporting diagnosis code that establishes medical necessity. The appropriate ICD-10-CM code depends on which clinical indication applies. Mismatching the ICD-10 code to the wrong indication is a common audit trigger, particularly when leucovorin is billed for methotrexate rescue but the primary diagnosis listed is a condition that does not typically involve high-dose methotrexate.

For methotrexate rescue billing, the primary diagnosis is typically the cancer being treated (e.g., C85.90 for lymphoma), with a secondary code capturing the adverse drug effect (T45.1X5A) if applicable. Consult the CDC/NCHS ICD-10-CM web tool to verify the most current code descriptors and sequencing guidance before claim submission.

Documentation requirements for J0640 claims

Documentation is where most J0640 audits are won or lost. Unlike a straightforward evaluation and management code, injectable drug claims require a paper trail that traces from the clinical order through to administration and then to the claim. Five documentation elements are non-negotiable for a defensible J0640 record.

• Drug name and strength: The medical record must clearly state “leucovorin calcium” (not just “leucovorin” or “folinic acid”) along with the concentration (e.g., 10 mg/mL) and total dose ordered.
• Route and dose administered: Document the actual dose given in mg, the route (IV push, IV infusion, IM, or subcutaneous), and the start and stop times for infusions. This is distinct from the ordered dose, which matters if a partial dose was given.
• Clinical indication: The note must state the reason leucovorin was given. “Leucovorin rescue per MTX protocol” or “per FOLFOX cycle 3 protocol” is sufficient. A vague note that says only “drug administered” will not survive payer review.
• NDC number and lot: Record the NDC from the vial label at the time of administration. Many practices attach a drug label to the administration record. The NDC on the chart must match the NDC submitted on the claim.
• Prescriber order: A signed order (or verbal order countersigned within the required timeframe) from the treating physician must be present. For chemotherapy-protocol administration, the signed protocol itself typically satisfies this requirement.

Practices using clinical records in Pabau can structure treatment notes to capture all five elements at the point of care. That removes the reconciliation step where billing staff hunt through multiple documents to build a complete claim package. Good medical record documentation at the clinical level is the most effective denial prevention strategy available.

For practices concerned about audit readiness, HIPAA-compliant documentation practices and proper record retention policies are also relevant here, as J0640 claims are subject to the same post-payment review processes as other Part B drug claims.

Prior authorization requirements

Medicare Part B generally does not require prior authorization for J0640 when leucovorin calcium is used as a methotrexate rescue agent or as part of a recognized chemotherapy regimen. However, commercial payers and Medicare Advantage plans vary significantly. PA requirements for leucovorin billing depend on:

• The specific payer and plan formulary
• The clinical indication (rescue vs. 5-FU modulation vs. anemia)
• Whether the drug is administered in an office or outpatient hospital setting
• The diagnosis linked to the claim

For commercial payers, check the payer’s formulary or use the provider portal to confirm PA status before the first administration. Retroactive PA approvals for administered drugs are granted inconsistently across payers. Protecting patient data security during PA submission processes is also important, as prior authorization portals involve sharing protected health information with payer systems.

When a PA is denied, the appeal should include the prescribing physician’s clinical rationale, the relevant treatment protocol (e.g., FOLFOX protocol documentation), and any supporting oncology society guidelines that reference leucovorin as a standard-of-care agent for the indicated condition.

Related HCPCS and CPT codes

J0640 rarely appears on a claim in isolation. Most leucovorin administrations are paired with at least one CPT administration code and often with companion drug codes. Understanding the code relationships prevents unbundling errors and incomplete claim submissions.

J0640 vs. J0641 (levoleucovorin): These are not interchangeable. J0641 describes levoleucovorin, the biologically active L-stereoisomer sold under brand names including Khapzory and Fusilev. Leucovorin calcium (J0640) is the racemic mixture. Submitting J0641 when racemic leucovorin was administered, or vice versa, is a coding error that can result in overpayment recovery or clinical record inconsistency.

Infusion practices that manage multiple chemotherapy agents benefit from EMR systems that support drug-specific billing workflows. Explore EMR software for infusion practices to understand what features reduce co-administration billing errors in oncology settings.

Conclusion

J0640 claims fail most often for preventable reasons: A missing NDC, a unit count based on vial size rather than administered dose, or an ICD-10 code that does not match the documented indication. Getting those three elements right at the point of care, not at the point of billing, is what separates practices with clean claim rates from those that spend weeks working denials.

Pabau helps oncology and infusion practices capture administered drug data, NDC numbers, and clinical indications in structured patient records, so the billing team always has what it needs before a claim is generated. Explore how Pabau supports claims management for injectable drug billing, or book a demo to see the workflow in practice.

Continue your research

Managing IV therapy compliance? IV therapy clinic best practices covers the operational and documentation standards that protect infusion practices during audits.

Looking for paperless documentation workflows? Going paperless in clinical practice explains how structured digital records reduce the documentation gaps that cause claim denials.

Need a broader oncology billing context? Lab management software from Pabau helps practices track specimen and test results alongside drug administration records for complete clinical documentation.

Frequently Asked Questions